Journey Medical Corp expected to post a loss of 14 cents a share - Earnings Preview

Journey Medical

10/08/2024 24:15

* Journey Medical Corp  DERM.OQ   DERM.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 12
for the period ending June 30 2024
    * The Scottsdale Arizona-based  company is expected to
report a
19.2% decrease in revenue to $13.88 million from $17.17 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Journey Medical Corp is
for a
loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Journey
Medical
Corp is $8.50​, above​ its last closing price of $4.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.23       -0.23      -0.53     Missed  -125.5
 Dec. 31 2024  -0.09       -0.08      -0.12     Missed  -56.5
 Sep. 30 2023  -0.11       -0.15      0.80      Beat    616.1​
 Jun. 30 2023  -0.35       -0.33      -0.29     Beat    13.4
 ​​Jan.        -0.45       -0.45      -0.57     Missed  -27.6
 1 0001                                                 
 Dec. 31 2022              -0.47      -0.60     Missed  -28.6​
 Sep. 30 2022  -0.50       -0.40      -0.57     Missed  -43.7
 Jun. 30 2022  -0.26       -0.26      -0.43     Missed  -67.5
 This summary was machine generated August 9 at 23:15 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)